UY34069A - Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia - Google Patents

Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia

Info

Publication number
UY34069A
UY34069A UY0001034069A UY34069A UY34069A UY 34069 A UY34069 A UY 34069A UY 0001034069 A UY0001034069 A UY 0001034069A UY 34069 A UY34069 A UY 34069A UY 34069 A UY34069 A UY 34069A
Authority
UY
Uruguay
Prior art keywords
semuloparine
cancer
patients
prevention
venous thromboembolism
Prior art date
Application number
UY0001034069A
Other languages
English (en)
Inventor
Umesh Chaudhari
Dominique Destree
Francesca Lawson
Guillaume Lecorps
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY34069A publication Critical patent/UY34069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La invención se refiere a una heparina de peso molecular ultra bajo con un peso molecular medio de 2000 a 3000 Daltons, una actividad anti-FXa de aproximadamente 160 U/mg y una actividad anti-FIIa de aproximadamente 2 U/mg, en particular semuloparina, para usarse como un agente antitrombótico para la profilaxis del tromboembolismo venoso en pacien tes con cáncer que reciben quimioterapia para tumores sólidos metastásicos o localmente avanzados, más específicamente en pacientes que reciben quimioterapia para cáncer de pulmón o de páncreas metastásico o localmente avanzado, o para tumores sólidos metastásicos o localmente avanzados con una pun tuación de riesgo de VTE igual a o mayor que 3.
UY0001034069A 2011-05-12 2012-05-11 Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia UY34069A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11305577 2011-05-12
EP11305981 2011-07-28
EP11306623 2011-12-07
EP12305435 2012-04-13

Publications (1)

Publication Number Publication Date
UY34069A true UY34069A (es) 2013-01-03

Family

ID=46051692

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034069A UY34069A (es) 2011-05-12 2012-05-11 Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia

Country Status (6)

Country Link
US (1) US20120322759A1 (es)
EP (1) EP2706990A1 (es)
JP (1) JP2014513193A (es)
AR (1) AR086349A1 (es)
UY (1) UY34069A (es)
WO (1) WO2012152918A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
AU2008255191A1 (en) * 2008-12-09 2010-06-24 Sanofi-Aventis Use of Ave5026 for minimizing the incidence of bleedings during an antithrombotic treatment

Also Published As

Publication number Publication date
EP2706990A1 (en) 2014-03-19
US20120322759A1 (en) 2012-12-20
WO2012152918A1 (en) 2012-11-15
JP2014513193A (ja) 2014-05-29
AR086349A1 (es) 2013-12-04

Similar Documents

Publication Publication Date Title
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
EA201400178A1 (ru) Лечение рака молочной железы
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
NI201600071A (es) Compuestos de inhibidor de autotaxina
ECSP15026557A (es) Compuestos y sus métodos de empleo
CO7190236A2 (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
CO7020912A2 (es) Inhibidores de bromodominios
NI201400073A (es) Compuestos terapéuticamente activos y sus método
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
MY167620A (en) Smoking article including dual heat-conducting elements
UY4167Q (es) Par de auriculares
EP3052131A4 (en) Methods for treating cancer in patients with elevated levels of bim
IL239007B (en) Eribulin for use in the treatment of breast cancer
BR112013024211A2 (pt) tratamento de tumores sólidos
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
UY34829A (es) Nueva dosificación y formulación
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140527